Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2026: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2025: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2024: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
Outline of Research at the Start |
A fundamental problem in leukemia treatment is how to overcome drug resistance. Leukemic cells evade drug effects by enhancing multidrug resistance protein 1 (MDR1; ABCB1 gene). MDR1 pumps foreign substances, including chemotherapeutic drugs, out of cells. Defective apoptosis is another drug resistance mechanism.
AIM1: Evaluate SLC5A5 expression in human hematopoietic/stromal cells of myeloid leukemia patients and normal controls before and after ATRA/dexamethasone or myelosuppression
AIM2. Determine proliferation/apoptosis after myelosuppression with/ without I- and I2 addition
|